Our Science

Despite transformative advances in oncology, therapy resistance remains the ultimate barrier to cure. Standard treatments—including chemotherapy, radiation, and immunotherapy—induce stress that enables tumors to adapt, survive, and relapse. No existing strategy fully addresses this core vulnerability.

Modunai Therapeutics pioneers a new precision approach—turning stress adaptation into a therapeutic opportunity. Our pipeline is built on two synergistic strategies:

Extrinsic Stress Modulation via Tumor-Targeted Bispecific Antibodies

We engineer AI-guided bispecific biologics that target stress mediators in the tumor microenvironment, dismantling immune-suppressive niches and sensitizing tumors to checkpoint inhibitors and chemoradiation.

Intrinsic Stress Targeting with pH-Selective Antibody–Drug Conjugates (ADCs)

We develop pH-selective ADCs that recognize stress pathways in resistant tumors. Integrated with theranostics, these ADCs detect and eliminate residual resistant clones, aiming for curative precision.

Together, Modunai's complementary platforms harness therapy-induced vulnerabilities to overcome resistance. Beyond oncology, our AI-driven stress biology platform extends to autoimmune and inflammatory diseases—transforming therapy resistance into durable remission.

Harnessing Stress-Adaptation Biology to Overcome Therapy Resistance

Tumor Relapse

Targeting Stress Adaptation in Cancer Resistance

Pipeline

Advancing AI-engineered bispecific antibodies and ADCs that modulate tumor stress pathways to overcome therapy resistance.

FAQs

What is Modunai Therapeutics?

Modunai Therapeutics is a biotechnology company pioneering stress-adaptation biology to eliminate therapy resistance in cancer and autoimmunity. We design AI-guided bispecific and antibody–drug conjugate (ADC) therapeutics that target the root causes of resistant and relapsing disease.

Why focus on therapy resistance?

Most cancers initially respond to chemotherapy, radiation, or immunotherapy—but eventually relapse as tumors adapt and survive. Modunai’s approach turns these stress-induced adaptations into vulnerabilities, enabling lasting remission.

How does Modunai’s technology work?

Our AI-enabled discovery platform integrates precision antibody engineering with insights from stress biology. We create tumor-selective bispecifics and pH-sensitive ADCs that reprogram resistant tumor microenvironments or directly eliminate residual cancer cells.

What therapeutic areas are you advancing?

Our lead programs target solid tumors and resistant cancers, with platform expansion into autoimmune diseases where similar stress-response mechanisms drive relapse.

How can I connect with Modunai for partnerships or investment opportunities?

We welcome collaboration with strategic partners, investors, and researchers who share our vision to transform therapy resistance into durable remission. Please reach out through our Contact page.